Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Moodys
Merck
Medtronic
AstraZeneca

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

ATROPEN Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Atropen patents expire, and what generic alternatives are available?

Atropen is a drug marketed by Meridian Medcl Techn and is included in one NDA.

The generic ingredient in ATROPEN is atropine. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the atropine profile page.

Drug patent expirations by year for ATROPEN
Recent Clinical Trials for ATROPEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Craig J. HuangN/A
University of PittsburghPhase 1
MicroDose Defense Products L.L.C.Phase 1

See all ATROPEN clinical trials

Synonyms for ATROPEN
(+-)-atropine
(+-)-hyoscyamine
(+,-)-Tropyl tropate
(+)-HYOSCYAMINE
(+/-)-Atropine
(+/-)-Hyoscyamine
(1beta,3alpha,5beta)-3-[(3-Hydroxy-1-oxo-2-phenylpropyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane
(1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate
(1S,5R)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenyl-propanoate
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoate
[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenyl-propanoate
1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester)
1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI)
13269-35-7
1445960-43-9
1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester)
2-Phenylhydracrylic acid 3-alpha-tropanyl ester
3-tropoyloxytropane
51-55-8
5908-99-6
78597-12-3
8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropionate
AB00694549_14
AB00694549-11
AB00694549-12
AC1L5AX3
AC1Q3XL2
ACon1_000046
AI3-60219
AKOS015955538
alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester
alpha-Hydroxymethylphenylacetic acid (1R,5S)-8-methyl-8-azabicyclo[3.2.1]octane-3-yl ester
Anaspaz
Atropair
Atropen (TN)
Atropin
Atropin [German]
Atropin-flexiolen
Atropina
Atropina [Italian]
ATROPINE
Atropine (USP)
Atropine [BAN]
Atropine [USP:BAN]
Atropine Care
Atropine for peak identification, European Pharmacopoeia (EP) Reference Standard
Atropine sulfate
Atropine Sulfate Ansyr Plastic Syringe
Atropine Sulfate S.O.P.
Atropine, >=95.0% (NT)
Atropine, >=99% (TLC), powder
Atropine, analytical standard
Atropine, European Pharmacopoeia (EP) Reference Standard
Atropine, meets USP testing specifications
Atropinol
Atropinum
Atropt
Atrosulf
b eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
BCP15060
BDBM200229
BDBM50403547
Belladenal
Benzeneacetic acid, alpha-(hydroxymethyl)- (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester
Benzeneacetic acid, alpha-(hydroxymethyl)- 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester endo-(+-)-
Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester
Benzeneacetic acid, alpha-(hydroxymethyl)-, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-(+-)-
Benzeneacetic acid, alpha-(hydroxymethyl)-, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-(+/-)-
Benzeneacetic acid, alpha-(hydroxymethyl)-8-methyl-8-azabicyclo [3.2.1]oct-3-yl ester, endo-(+/-)-
Benzeneacetic acid, alpha-(hydroxymethyl)-8-methyl-8-azabicyclo(3,2,1)oct-3-yl ester, endo-(+-)-
Benzeneacetic acid, alpha-(hydroxymethyl)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-(+-)-
Benzeneacetic acid, alpha-(hydroxymethyl)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester endo-(+-)-
beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester
beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]
beta-Phenyl-gamma-oxypropionsaure-tropyl-ester
beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]
bmse000649
BRD-A27290375-001-01-8
BRD-A27290375-330-01-1
C01479
C1504
C17H23NO3
CAS-51-55-8
CCRIS 3080
CHEBI:16684
CHEBI:78734
CHEMBL475124
CHEMBL517712
cid_174174
CPD001906768
CS-4834
Cytospaz
D00113
DB00572
dl-Hyoscyamine
DL-Tropanyl 2-hydroxy-1-phenylpropionate
DL-Tropyl tropate
dl-Tropyltropate
Donnagel
DSSTox_CID_113
DSSTox_GSID_20113
DSSTox_RID_75375
DTXSID4020113
EINECS 200-104-8
endo-( inverted exclamation markA)-|A-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
Eyesules
FT-0602865
FT-0627165
GP2470
GTPL320
HMS2089A16
HMS2231G17
HMS3259M13
HSDB 2199
HY-B1205
hyoscyamine
Hyoscyamine sulfate
I-Tropine
Isopto Atropine
Isopto-atropine
L-Hyoscyamine
LS-7203
MEGxp0_001878
MFCD00022622
Minims
Minims Atropine
MLS000069795
MLS001148094
MLS002695888
MolPort-001-742-593
Mydriasine
NC00493
NCGC00017333-02
NCGC00017333-03
NCGC00017333-04
NCGC00017333-05
NCGC00017333-06
NCGC00142514-01
NCGC00142514-03
NCGC00159345-02
NCGC00258041-01
NCGC00385525-01
Neo-Diophen
Ocu-Tropine
Opera_ID_1088
Protamine & Atropine
rac-(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
rac-tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate
RKUNBYITZUJHSG-SPUOUPEWSA-N
RL00080
ropine tropate
SAM002554885
SBB005985
SCHEMBL2812
SMR000058248
ST057178
Tox21_110816
Tox21_111590
Tox21_200487
TR-000361
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate
Tropic acid, 3-alpha-tropanyl ester
Tropic acid, ester with tropine
Tropine (+/-)-tropate
Tropine tropate
Tropine, tropate (ester)
Troyl tropate
Urised

US Patents and Regulatory Information for ATROPEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Meridian Medcl Techn ATROPEN atropine SOLUTION;INTRAMUSCULAR 017106-004 Sep 17, 2004 RX Yes Yes   Start Trial   Start Trial   Start Trial
Meridian Medcl Techn ATROPEN atropine SOLUTION;INTRAMUSCULAR 017106-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
Meridian Medcl Techn ATROPEN atropine SOLUTION;INTRAMUSCULAR 017106-003 Jun 19, 2003 RX Yes Yes   Start Trial   Start Trial   Start Trial
Meridian Medcl Techn ATROPEN atropine SOLUTION;INTRAMUSCULAR 017106-002 Jun 19, 2003 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
McKinsey
Mallinckrodt
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.